Immunic (IMUX) investor relations material

Executive summary

• Focused on late-stage development of novel oral therapies for neurologic diseases, with lead candidate vidofludimus calcium in Phase 3 trials for multiple sclerosis (MS).

• Expanded leadership team with new CEO, CMO, and Chair to support clinical development and commercial readiness.

• No commercial products or product revenue to date; operations funded by equity offerings and warrants.

• Well-capitalized following oversubscribed private placement, with cash runway into late 2027.

• Preparing for Phase 3 trial in progressive MS, leveraging positive Phase 2 CALLIPER data.

Financial highlights

• Net loss of $34.1 million for Q2 2026, up from $26.8 million in Q2 2025; six-month net loss of $66.7 million, up from $52.3 million year-over-year.

• Operating expenses rose 30% year-over-year for the quarter, driven by increased R&D and G&A costs, including higher non-cash stock compensation.

• Cash and cash equivalents of $155.1 million as of June 30, 2026, up from $15.5 million at year-end 2025, primarily due to a $200 million private placement in February 2026.

• Total stockholders' equity improved to $127.6 million as of June 30, 2026, from a deficit of $6.7 million at year-end 2025.

• R&D expenses for Q2 2026 were $25.9 million, up $4.6 million year-over-year, mainly due to personnel and NDA-supporting studies.

Outlook and guidance

• Sufficient cash to fund operations into late 2027.

• Top-line data from twin Phase 3 ENSURE trials in relapsing MS expected by end of 2026; potential NDA filing in mid-2027 and possible U.S. approval in 2028.

• Phase 3 trial in progressive MS planned for initiation later in 2026.